Duloxetine hydrochloride (brand names: Cymbalta/Yentreve) is a medically used drug that primarily targets major depressive disorders (MDD), pain related to diabetic peripheral neuropathy and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-2-thiophenepropanamine, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE and 5-HT transport sites. Its behavior contrasts to most other dual-reuptake inhibitors in that Ki values are nearly 1:1.
Furthermore, duloxetine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours. Most common side effects in clinical trials were nausea, somnolence, and dry mouth. In clinical trials weight gain was neutral compared to placebo. Five people, including a 19-year old college student committed suicide while Eli Lilly was conducting preliminary trials. Ongoing studies including a 52 week safety and efficacy trial are available at [http://www.lillytrials.com www.lillytrials.com. Long-term side-effects seen in these trials did not vary from the original approval studies.
Duloxetine is approved by the FDA for the treatment of diabetic neuropathy. Approved dosages for treatment of diabetic peripheral neuropathic pain are 60 mg and 120 mg once daily.
More on [ Duloxetine ]
Antidepressants :: Drugs and Medications

APA: Duloxetine Has Little Effect on Body Weight - Report on research findings announced at meeting in May 2002.
Cymbalta - Manufacturer's site for this selective serotonin and norepinephrine reuptake inhibitor (SSNRI), approved in the US to treat diabetic peripheral neuropathic pain and major depression.
Duloxetine Antidepressant Action Begins in One Week - Report on study findings announced in October 2002. [MedScape - Free registration required.]
Duloxetine for Major Depressive Disorder: A Randomized Double-Blind Placebo-Controlled Trial - Abstract of study findings published in April 2002.
Duloxetine: Lilly Receives Approvable Letter - News on FDA action in September 2002 related to the dual 5HT/noradrenaline reuptake inhibitor (also known as Cymbalta) for the treatment of depression.
Meta Description: [ Sankyo withdrawn, Warner Lambert Japan, USA ]
| Caution on Liver Damage and Cymbalta (Jan. 2006) | |
| Next Video | |